Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
71,366,920
-
Total 13F shares
-
64,180,724
-
Share change
-
+3,082,655
-
Total reported value
-
$365,858,797
-
Put/Call ratio
-
8.2%
-
Price per share
-
$5.70
-
Number of holders
-
121
-
Value change
-
+$21,073,780
-
Number of buys
-
66
-
Number of sells
-
56
Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) as of Q3 2024
As of 30 Sep 2024,
C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,180,724 shares.
The largest 10 holders included
Lynx1 Capital Management LP, Soleus Capital Management, L.P., WASATCH ADVISORS LP, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, COMMODORE CAPITAL LP, VANGUARD GROUP INC, STATE STREET CORP, and MORGAN STANLEY.
This page lists
118
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.